These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 18706956)

  • 1. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses.
    Mahmood K; Bright RA; Mytle N; Carter DM; Crevar CJ; Achenbach JE; Heaton PM; Tumpey TM; Ross TM
    Vaccine; 2008 Oct; 26(42):5393-9. PubMed ID: 18706956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of influenza H7N9 virus like particle (VLP) vaccine: homologous A/Anhui/1/2013 (H7N9) protection and heterologous A/chicken/Jalisco/CPA1/2012 (H7N3) cross-protection in vaccinated mice challenged with H7N9 virus.
    Smith GE; Flyer DC; Raghunandan R; Liu Y; Wei Z; Wu Y; Kpamegan E; Courbron D; Fries LF; Glenn GM
    Vaccine; 2013 Sep; 31(40):4305-13. PubMed ID: 23891795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge.
    Govorkova EA; Webby RJ; Humberd J; Seiler JP; Webster RG
    J Infect Dis; 2006 Jul; 194(2):159-67. PubMed ID: 16779721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge.
    Haynes JR; Dokken L; Wiley JA; Cawthon AG; Bigger J; Harmsen AG; Richardson C
    Vaccine; 2009 Jan; 27(4):530-41. PubMed ID: 19026705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flagellin-HA vaccines protect ferrets and mice against H5N1 highly pathogenic avian influenza virus (HPAIV) infections.
    Liu G; Song L; Reiserova L; Trivedi U; Li H; Liu X; Noah D; Hou F; Weaver B; Tussey L
    Vaccine; 2012 Nov; 30(48):6833-8. PubMed ID: 23000130
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reverse micelle-encapsulated recombinant baculovirus as an oral vaccine against H5N1 infection in mice.
    Prabakaran M; Madhan S; Prabhu N; Geng GY; New R; Kwang J
    Antiviral Res; 2010 May; 86(2):180-7. PubMed ID: 20153776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative efficacy of North American and antigenically matched reverse genetics derived H5N9 DIVA marker vaccines against highly pathogenic Asian H5N1 avian influenza viruses in chickens.
    Jadhao SJ; Lee CW; Sylte M; Suarez DL
    Vaccine; 2009 Oct; 27(44):6247-60. PubMed ID: 19686695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivated and adjuvanted whole-virion clade 2.3.4 H5N1 pre-pandemic influenza vaccine possesses broad protective efficacy against infection by heterologous clades of highly pathogenic H5N1 avian influenza virus in mice.
    Harada Y; Ninomiya-Mori A; Takahashi Y; Shirakura M; Kishida N; Kageyama T; Tada Y; Tashiro M; Odagiri T
    Vaccine; 2011 Oct; 29(46):8330-7. PubMed ID: 21911027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical evaluation of a modified vaccinia virus Ankara (MVA)-based vaccine against influenza A/H5N1 viruses.
    Kreijtz JH; Suezer Y; de Mutsert G; van den Brand JM; van Amerongen G; Schnierle BS; Kuiken T; Fouchier RA; Löwer J; Osterhaus AD; Sutter G; Rimmelzwaan GF
    Vaccine; 2009 Oct; 27(45):6296-9. PubMed ID: 19840663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigation of the biological indicator for vaccine efficacy against highly pathogenic avian influenza (HPAI) H5N1 virus challenge in mice and ferrets.
    Song MS; Oh TK; Pascua PN; Moon HJ; Lee JH; Baek YH; Woo KJ; Yoon Y; Sung MH; Poo H; Kim CJ; Choi YK
    Vaccine; 2009 May; 27(24):3145-52. PubMed ID: 19446184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemagglutinin displayed baculovirus protects against highly pathogenic influenza.
    Tang XC; Lu HR; Ross TM
    Vaccine; 2010 Oct; 28(42):6821-31. PubMed ID: 20727393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets.
    Lipatov AS; Hoffmann E; Salomon R; Yen HL; Webster RG
    J Infect Dis; 2006 Oct; 194(8):1040-3. PubMed ID: 16991078
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influenza virus-like particles produced by transient expression in Nicotiana benthamiana induce a protective immune response against a lethal viral challenge in mice.
    D'Aoust MA; Lavoie PO; Couture MM; Trépanier S; Guay JM; Dargis M; Mongrand S; Landry N; Ward BJ; Vézina LP
    Plant Biotechnol J; 2008 Dec; 6(9):930-40. PubMed ID: 19076615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine.
    Baras B; Stittelaar KJ; Simon JH; Thoolen RJ; Mossman SP; Pistoor FH; van Amerongen G; Wettendorff MA; Hanon E; Osterhaus AD
    PLoS One; 2008 Jan; 3(1):e1401. PubMed ID: 18167560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle.
    Bright RA; Carter DM; Crevar CJ; Toapanta FR; Steckbeck JD; Cole KS; Kumar NM; Pushko P; Smith G; Tumpey TM; Ross TM
    PLoS One; 2008 Jan; 3(1):e1501. PubMed ID: 18231588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of certain DNA vaccine combinations expressing different H5N1 influenza virus antigens can be beneficial or detrimental to immune protection.
    Patel A; Gray M; Li Y; Kobasa D; Yao X; Kobinger GP
    Vaccine; 2012 Jan; 30(3):626-36. PubMed ID: 22119588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.